Acute central nervous system inflammation presents an urgent diagnostic emergency. Clinicians must identify the causative organism rapidly to initiate targeted therapy and prevent irreversible neurological damage. However, conventional microbiological assays frequently fail to identify the etiology. The emergence of mNGS in viral encephalitis offers an unbiased approach to pathogen detection. By sequencing all nucleic acids present within cerebrospinal fluid, this technology helps clinicians identify rare, atypical, or emerging neurotropic pathogens when routine investigations remain non-diagnostic.

Diagnostic Hurdles in Viral Encephalitis and the Shift to Unbiased Sequencing

Acute viral encephalitis demands prompt therapeutic intervention to minimize long-term morbidity. Unfortunately, standard diagnostic tools leave more than half of suspected cases entirely unexplained. Traditional diagnostic approaches rely heavily on targeted real-time polymerase chain reaction, serological antibody detection, and viral culture. Although multiplex neurotropic panels have expanded diagnostic efficiency, they remain limited by pre-selected pathogen targets. Consequently, these targeted assays fail whenever an atypical, mutated, or novel infectious agent causes the disease. Furthermore, the timing of lumbar puncture critically dictates diagnostic yield. For instance, viral titers in cerebrospinal fluid often peak briefly and clear rapidly before clinicians perform a lumbar puncture. In addition, localized parenchymal inflammation without significant shedding into cerebrospinal fluid yields false-negative molecular tests. Serological evaluations also present distinct challenges because antibody responses require days to develop. Therefore, early serology frequently produces negative or indeterminate results, delaying critical management decisions. These persistent gaps highlight why clinicians require innovative methods to detect unanticipated pathogens. Unbiased metagenomic sequencing circumvents these boundaries by capturing all microbial genetic material. Thus, this sequencing strategy enables broad, pathogen-agnostic identification without requiring clinicians to hypothesize the specific causative organism beforehand.

Sequencing Platforms and Technical Variations in Diagnostic Yield

The technical architecture of metagenomic sequencing directly dictates clinical sensitivity and turnaround speed. Currently, short-read sequencing platforms such as Illumina hold the largest body of clinical evidence. These short-read technologies provide high throughput, exceptional base accuracy, and robust quantitative depth. However, batch-dependent sequencing protocols often lengthen turnaround times to several days, which limits their utility in acute neurological emergencies. In contrast, long-read platforms like Oxford Nanopore provide real-time data streaming and rapid library preparation. Consequently, nanopore technology can deliver actionable pathogen detection within hours of cerebrospinal fluid collection. Nevertheless, long-read sequencing still demonstrates higher error rates and requires rigorous site-specific validation before clinical implementation. Furthermore, technical variations across laboratory workflows significantly impact clinical yield. For example, pre-analytical sample handling, host nucleic acid depletion, and extraction efficiencies alter pathogen detection limits. Because human host DNA typically represents over ninety-nine percent of total reads in cerebrospinal fluid, efficient human background depletion becomes paramount. Moreover, sequencing depth and customized bioinformatics pipelines define whether a laboratory detects low-titer neurotropic RNA viruses. Therefore, standardized laboratory protocols remain imperative to ensure reproducibility and reliable diagnostic accuracy across diverse hospital centers.

Clinical Utility and Practical Applications of mNGS in Viral Encephalitis

Clinicians increasingly recognize the diagnostic power of mNGS in viral encephalitis when standard testing fails. Observational studies demonstrate that metagenomic profiling frequently uncovers unexpected neurotropic pathogens. For instance, mNGS has successfully identified neuroinvasive astroviruses, bornaviruses, enteroviruses, and tick-borne arboviruses that standard panels routinely omit. In addition, the assay proves especially valuable in immunocompromised individuals. Transplant recipients and patients with human immunodeficiency virus often experience opportunistic central nervous system infections. Specifically, mNGS reliably detects cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 reactivations in vulnerable patient populations. Furthermore, metagenomic analysis identifies atypical presentations of common pathogens, including herpes simplex virus and varicella-zoster virus, when targeted molecular tests remain inconclusive. Notably, identifying the exact etiology prevents prolonged empiric antimicrobials and shortens intensive care stays. In other circumstances, confirming a pathogen-free metagenomic profile gives clinicians the confidence to initiate immunosuppressive therapy for autoimmune encephalitis. However, clinicians must not view metagenomics as a standalone first-line replacement for standard multiplex assays. Instead, metagenomics serves as an indispensable, early complementary test that resolves complex diagnostic dilemmas in deteriorating patients.

Navigating Bioinformatic Thresholds and Orthogonal Confirmation

Interpreting metagenomic sequencing data requires rigorous bioinformatic filtering and clinical adjudication. Cerebrospinal fluid samples typically contain minute quantities of viral nucleic acids alongside environmental contaminants. Therefore, laboratories must establish strict quality-control thresholds to separate true clinical pathogens from background noise. Bioinformatics pipelines assess total read counts, unique sequence coverage, and genome depth against continuous negative controls. In addition, environmental microbes, skin flora, and laboratory reagents can introduce contaminating sequences during sample processing. Consequently, clinicians must evaluate every positive sequencing result within the patient’s clinical and epidemiological context. For example, detecting torque teno virus or skin commensals rarely explains acute necrotizing encephalitis. Conversely, detecting even a few specific sequence reads of rabies or eastern equine encephalitis virus demands urgent action. Furthermore, clinicians must corroborate unexpected sequencing hits using orthogonal confirmatory methods. Validated real-time polymerase chain reaction, serological neutralization assays, or digital droplet PCR confirm the metagenomic finding. Clinicians must also remember that a negative sequencing result never completely excludes infection. Low viral copy numbers, localized tissue sequestration, or delayed sampling can cause false negatives. Thus, multidisciplinary microbial boards provide critical guidance when interpreting complex metagenomic findings.

A Pragmatic Decision Pathway for Clinical Practice

Integrating metagenomics into clinical neurology workflows requires a structured, stepwise diagnostic algorithm. When a patient presents with acute encephalopathy, clinicians must immediately initiate empirical therapy and collect cerebrospinal fluid. First, physicians should execute urgent targeted testing, including rapid multiplex PCR panels, neuroimaging, and basic cerebrospinal fluid cytology. If initial testing confirms a common pathogen, clinicians can promptly refine antimicrobial therapy without expensive genomic investigations. However, if the patient deteriorates or routine assays remain negative after forty-eight hours, clinicians should reflex to metagenomic sequencing. Moreover, clinicians should consider early metagenomic sequencing upfront for severely immunocompromised patients and individuals with atypical encephalitis presentations. Simultaneously, clinicians must preserve an adequate cerebrospinal fluid aliquot under ultra-low freezing temperatures for subsequent genomic testing. This pre-planned biobanking prevents repeat invasive lumbar punctures in critically ill patients. Furthermore, healthcare teams must integrate clinical history, geographical exposures, and magnetic resonance imaging findings when reviewing sequencing reports. If sequencing identifies a plausible virus, clinicians adjust antiviral medications and initiate appropriate supportive care. Ultimately, this rational tiered approach balances diagnostic efficiency, cost-effectiveness, and optimal patient outcomes in complex neurological infections.

What is the primary role of mNGS in viral encephalitis diagnostics?

Metagenomic next-generation sequencing functions primarily as a powerful complementary diagnostic tool rather than a routine first-line replacement for standard PCR panels. Clinicians deploy this unbiased technology when initial multiplex testing leaves severe, progressive, or atypical encephalitis unexplained. In addition, it proves exceptionally valuable for immunocompromised patients susceptible to rare opportunistic pathogens. By sequencing all nucleic acids without prior hypotheses, it uncovers unanticipated pathogens and guides tailored clinical management.

How do false-negative and false-positive results occur during mNGS?

False-positive results typically arise from environmental contaminants, reagent impurities, or harmless colonizing microbes introduced during specimen collection and library preparation. Consequently, laboratories utilize strict bioinformatic thresholds and negative controls to filter these artifacts. Conversely, false negatives occur when viral loads drop below analytical detection thresholds, or when pathogens remain sequestered in brain tissue. Furthermore, delayed lumbar punctures and robust host immune responses can clear viral nucleic acids before sequencing begins.

When should clinicians order mNGS instead of standard PCR panels?

Clinicians should not order metagenomic sequencing instead of standard PCR panels, but rather as an escalated or concurrent investigation. Urgent targeted PCR remains faster and highly sensitive for common pathogens like herpes simplex virus. However, clinicians should promptly order metagenomic sequencing when initial investigations remain negative, when patients exhibit progressive neurological deterioration, or when travel history suggests rare neurotropic viruses. Early testing also benefits immunocompromised individuals facing atypical viral infections.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Binay UD et al. Metagenomic next-generation sequencing in the diagnosis of viral encephalitis. World J Virol. 2026 Sep 25. doi: 10.5501/wjv.124097. PMID: 42781247.
2. Wilson MR, Sample HA, Zorn KC, et al. Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis. N Engl J Med. 2019;380(24):2327-2340.
3. Ramachandran PS, Wilson MR. Metagenomics for neurological infections-expanding our understanding of neurotropic pathogens. Neurotherapeutics. 2020;17(2):477-487.
4. Pan X, Zhang Y, Chen G. The clinical utility of metagenomic next-generation sequencing for the diagnosis of central nervous system infectious diseases. Neurol Res. 2023;45(10):919-925.